Oric(US:ORIC) Benzinga·2025-11-07 21:30Core Insights - ORIC Pharmaceuticals, Inc. has granted inducement equity awards to a new non-executive employee as part of its 2022 Inducement Equity Incentive Plan [1][2][3] Summary by Sections Inducement Grants - A total of 18,400 non-qualified stock options and 3,000 restricted stock units were granted on November 3, 2025, to a new employee who started in October 2025 [1] - The stock options have an exercise price equal to the closing price of ORIC's common stock on the Grant Date [2] - Vesting schedule includes 25% of stock options vesting on the one-year anniversary, with the remaining shares vesting monthly thereafter, and one-third of restricted stock units vesting on each of the first three anniversaries [2] Compliance and Approval - The inducement grants were approved by ORIC's Compensation Committee in accordance with Nasdaq Rule 5635(c)(4) [3] - The grants were made as a material inducement to employment, complying with Nasdaq regulations [3] Company Overview - ORIC Pharmaceuticals is focused on developing treatments for therapeutic resistance in cancer, with clinical candidates including ORIC-944 for prostate cancer and enozertinib (ORIC-114) targeting various genetically defined cancers [4]